Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

• Status: Completed
• Trial end date: 2004-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Treatments: Bupropion; Nicotine

Criteria

Inclusion Criteria:

• Meets DSM-IV criteria for schizophrenia or schizoaffective disorder

• Receiving a stable dose of antipsychotic medication for at least 1 month prior to study entry

• Smokes at least 10 cigarettes per day

• Wishes to stop smoking

• Attended last three scheduled clinic visits, prior to study entry

Exclusion Criteria:

• Significant medical or neurologic illness

• History of severe head injury with loss of consciousness

• Treated with monoamine oxidase inhibitors or carbamazepine in the 14 days prior to study entry

• Taking clozapine at doses greater than 500 mg/d without an anticonvulsant

• Currently undergoing an acute exacerbation of psychotic symptoms

• Current or history of bulimia or anorexia

• Current excessive water intake

• Recent history of mania

• Known allergy or hypersensitivity to bupropion

• Current substance abuse other than tobacco, nicotine replacement treatment, or smokeless tobacco

• Currently receiving treatment with bupropion

• Pregnant or breastfeeding